Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 33.94% | -264.39% | 172.86% | 23.68% | -36.17% |
| Total Depreciation and Amortization | -5.33% | 14.19% | 8.82% | -2.86% | -4.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -110.78% | 102.12% | -700.21% | -784.60% | -137.37% |
| Change in Net Operating Assets | 51.12% | -141.67% | 340.69% | -147.62% | 12,500.00% |
| Cash from Operations | 33.31% | -5.28% | 14.57% | -40.09% | -18.49% |
| Capital Expenditure | -650.00% | 111.76% | -78.95% | -46.15% | -116.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7,300.69% | -97.76% | -36.38% | 141.66% | -1,013.99% |
| Cash from Investing | 7,191.78% | -97.72% | -36.49% | 141.61% | -1,012.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -89.33% | 56.14% | 590.91% | -85.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -89.33% | 56.14% | -99.24% | 13,307.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | -- | -100.00% |
| Net Change in Cash | 176.88% | -1,261.50% | -128.89% | 112.28% | -114.24% |